Labcorp Lifts Outlook as 2Q Profit, Revenue Rise

Dow Jones07-30

Labcorp raised its outlook for the year after it logged higher profit and revenue in the second quarter, boosted by growth in its diagnostic laboratories business.

The company on Thursday posted a profit of $298.7 million, or $3.64 a share, up from $237.9 million, or $2.84 a share, a year earlier.

Stripping out certain one-time items, earnings came in at $4.99 a share. Analysts polled by FactSet expected adjusted earnings of $4.78 a share.

Total revenue rose 5.8% to $3.73 billion, just ahead of Wall Street models for $3.71 billion.

Revenue across the company's diagnostics laboratories segment was up 5.5% to $2.9 billion.

Looking ahead, Labcorp raised its full-year adjusted earnings outlook to $18.10 to $18.55 a share, from $17.70 to $18.35 a share. The company also lifted its revenue forecast to $14.71 billion to $14.83 billion, from $14.65 billion to $14.8 billion.

Analysts are looking for adjusted earnings of $18.02 a share on revenue of $14.71 billion.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655424879?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 19:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655424879","market":"other","top_or_hot":-1,"title":"Labcorp Lifts Outlook as 2Q Profit, Revenue Rise","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Labcorp raised its outlook for the year after it logged higher profit and revenue in the second quarter, boosted by growth in its diagnostic laboratories business. \n</p>\n<p>\n  The company on Thursday posted a profit of $298.7 million, or $3.64 a share, up from $237.9 million, or $2.84 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, earnings came in at $4.99 a share. Analysts polled by FactSet expected adjusted earnings of $4.78 a share. \n</p>\n<p>\n  Total revenue rose 5.8% to $3.73 billion, just ahead of Wall Street models for $3.71 billion. \n</p>\n<p>\n  Revenue across the company's diagnostics laboratories segment was up 5.5% to $2.9 billion. \n</p>\n<p>\n  Looking ahead, Labcorp raised its full-year adjusted earnings outlook to $18.10 to $18.55 a share, from $17.70 to $18.35 a share. The company also lifted its revenue forecast to $14.71 billion to $14.83 billion, from $14.65 billion to $14.8 billion. \n</p>\n<p>\n  Analysts are looking for adjusted earnings of $18.02 a share on revenue of $14.71 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp Lifts Outlook as 2Q Profit, Revenue Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp Lifts Outlook as 2Q Profit, Revenue Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-30 19:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Labcorp raised its outlook for the year after it logged higher profit and revenue in the second quarter, boosted by growth in its diagnostic laboratories business. \n</p>\n<p>\n  The company on Thursday posted a profit of $298.7 million, or $3.64 a share, up from $237.9 million, or $2.84 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, earnings came in at $4.99 a share. Analysts polled by FactSet expected adjusted earnings of $4.78 a share. \n</p>\n<p>\n  Total revenue rose 5.8% to $3.73 billion, just ahead of Wall Street models for $3.71 billion. \n</p>\n<p>\n  Revenue across the company's diagnostics laboratories segment was up 5.5% to $2.9 billion. \n</p>\n<p>\n  Looking ahead, Labcorp raised its full-year adjusted earnings outlook to $18.10 to $18.55 a share, from $17.70 to $18.35 a share. The company also lifted its revenue forecast to $14.71 billion to $14.83 billion, from $14.65 billion to $14.8 billion. \n</p>\n<p>\n  Analysts are looking for adjusted earnings of $18.02 a share on revenue of $14.71 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PMDE","symbol_name":"PGIM S&P 500 Max Buffer ETF - December","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2655424879","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655424879","pubTimestamp":1785409980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Labcorp raised its outlook for the year after it logged higher profit and revenue in the second quarter, boosted by growth in its diagnostic laboratories business.The company on Thursday posted a profit of $298.7 million, or $3.64 a share, up from $237.9 million, or $2.84 a share, a year earlier.Stripping out certain one-time items, earnings came in at $4.99 a share. Analysts polled by FactSet expected adjusted earnings of $4.78 a share.Total revenue rose 5.8% to $3.73 billion, just ahead of Wall Street models for $3.71 billion.Revenue across the company's diagnostics laboratories segment was up 5.5% to $2.9 billion.Looking ahead, Labcorp raised its full-year adjusted earnings outlook to $18.10 to $18.55 a share, from $17.70 to $18.35 a share. The company also lifted its revenue forecast to $14.71 billion to $14.83 billion, from $14.65 billion to $14.8 billion.Analysts are looking for adjusted earnings of $18.02 a share on revenue of $14.71 billion.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PMDE":"PGIM S&P 500 Max Buffer ETF - December","BK4585":"ETF&股票定投概念","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","VGFPF":"Vanguard Funds PLC","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","VOTE":"TCW Transform 500 ETF","GXDW":"Global X Dorsey Wright Thematic ETF","LU0251142724.SGD":"Fidelity America A-SGD","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","RGLO":"Global Equity Active ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","BK4588":"碎股","BK4550":"红杉资本持仓","LH":"徕博科","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4196":"保健护理服务","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC"},"translate_title":"随着第二季度利润和收入增长，Labcorp 上调前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOTE":0.72,"DECU":0.72,"JOYT":0.72,"GXDW":0.72,"PMDE":0.72,"RGLO":0.72,"VGFPF":0.72,"FEBU":0.72,"LH":0.9},"content_text":"Labcorp raised its outlook for the year after it logged higher profit and revenue in the second quarter, boosted by growth in its diagnostic laboratories business. \n\n\n  The company on Thursday posted a profit of $298.7 million, or $3.64 a share, up from $237.9 million, or $2.84 a share, a year earlier. \n\n\n  Stripping out certain one-time items, earnings came in at $4.99 a share. Analysts polled by FactSet expected adjusted earnings of $4.78 a share. \n\n\n  Total revenue rose 5.8% to $3.73 billion, just ahead of Wall Street models for $3.71 billion. \n\n\n  Revenue across the company's diagnostics laboratories segment was up 5.5% to $2.9 billion. \n\n\n  Looking ahead, Labcorp raised its full-year adjusted earnings outlook to $18.10 to $18.55 a share, from $17.70 to $18.35 a share. The company also lifted its revenue forecast to $14.71 billion to $14.83 billion, from $14.65 billion to $14.8 billion. \n\n\n  Analysts are looking for adjusted earnings of $18.02 a share on revenue of $14.71 billion.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655424879","isCrawlerRequest":true}